Microbiological Quality Control of Biotechnological Pharmaceuticals

On the Possibility of Reducing the Sample Size for Microbiological Examination of Some Pharmaceutical Substances

“…Drugs intended for prevention and treatment of disease received special attention during the COVID-19 epidemic [ 4 ]. The production of substances to manufacture such drugs can be expensive and time-consuming [ 5 ] although many people experience a vital need for these drugs that can ameliorate and/or avoid complications associated with a novel coronavirus infection.…”